Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00675350 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
A Phase 1 study of Hematologic Tumors, sponsored by ChemGenex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT00675350 is a Phase 1 study of Hematologic Tumors that has completed, run by ChemGenex Pharmaceuticals. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00675350, a Phase 1 study of Hematologic Tumors, has completed, sponsored by ChemGenex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
Conditions Studied
Interventions
- DRUG Omacetaxine
Study Locations (1)
Texas
- Mary Crowley Cancer Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00675350
The ClinicalTrials.gov registry entry for NCT00675350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ChemGenex Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Tumors appearing as the primary indexed condition, and to 1 intervention - of which Omacetaxine is the first listed.
NCT00675350 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00675350 about?
NCT00675350 is a clinical study titled "Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors". PK Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors
What is the current status of trial NCT00675350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-04. Estimated completion is 2009-01.
What conditions does trial NCT00675350 study?
This clinical trial studies the following conditions: Hematologic Tumors.
What interventions are being tested in trial NCT00675350?
The interventions under investigation include: Omacetaxine (DRUG).
Who is sponsoring clinical trial NCT00675350?
This trial is sponsored by ChemGenex Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00675350 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.